PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Phoenix Marcom Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bridge4Bio Teams with Instream Partners to Focus on Investment Advice - Life sciences and biotechnology organizations needing to raise capital or quickly identify corporate partners or merger/acquisition candidates worldwide can now benefit from receiving sound, focused investment advise
Bridge4Bio Teams with Instream Partners to Focus on Investment Advice

 

NewswireToday - /newswire/ - Cambridge, Cambs, United Kingdom, 2010/06/18 - Life sciences and biotechnology organizations needing to raise capital or quickly identify corporate partners or merger/acquisition candidates worldwide can now benefit from receiving sound, focused investment advise.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Life sciences and biotechnology organizations needing to raise capital or quickly identify corporate partners or merger/acquisition candidates worldwide can now benefit from receiving sound, focused investment advice following a collaborative pact forged between Bridge4Bio, LLC and Instream Partners, a FINRA member and leading investment banking and advisory corporate financial group.

An international life sciences business consulting firm based in Kensington, California, Bridge4Bio is now working closely with Instream Partners of Menlo Park, California to offer effective strategic corporate financial advisory assistance.

This strategic collaboration anchors Bridge4Bio’s ability to assist start-ups and medium-sized companies in life science and biotechnology sectors to quickly and efficiently identify the best methods of raising capital in targeted markets.

Bridge4Bio’s global team of senior consultants, now 10 strong, is highly skilled at guiding companies to identify appropriate distribution channels for a specific territory or technology sector. The consultancy also has the knowledge and expertise to select appropriate partners worldwide for OEM mergers or licensing deals to help broaden the business opportunities and prospects of life sciences and biotechnology companies.

In summarizing the advantages of the new partnership, Hugh Douglas, President of Bridge4Bio said: “Many companies can waste many months seeking capital from a variety of connections. Through lack of focus they often find they reach a financial dead end and face the prospect of losing what investment they have managed to attain. By going to Instream Partners from the outset, the payback is faster.

Instream’s advice can make an impact with immediate effect. If funding cannot be raised, they will say so without delay. But if there is a creative way to achieve to the same goal, it will be recommended. Instream’s advice is tailored to address each situation.”

Douglas continued, “Instream’s experience enables the quickest path to long term success. All companies need to grow to survive, and it is essential to bring in the best if you want to survive in these difficult and rocky financial times. Our consulting group is incredibly impressed with the professionalism and advice that we have received in identifying investment partners for our clients from Instream Partners. The track record of Instream and its Managing Director, Bob Harris, in helping our clients is compelling.”

“The collaboration with Bridge4Bio (bridge4bio.com) is a winning formula,” stated Harris. “Hugh Douglas and his team have brought in excellent candidates and technologies that could use capital and that truly would benefit with the services we offer. Bridge4Bio does a good job of screening companies so that we can immediately help them find the best route to their long term financial goals.”

Harris continued: “These days unless you have a rich relative with long arms and deep pockets, funds for organic growth are scarce. If you are to have growth and to reach the level where you can attract conventional sources of capital – commercial bank, venture capital and/or private equity or that available through public markets – and if you want liquidity, you need to consider mergers and acquisitions (M&A) as a way to reach that level. Ultimately to be attractive as an M&A candidate for a major life sciences or health care company, you will need to have capable management, manufacturing capability, technology, and an established sales and service infrastructure, or you will need to target and buy or merge with such companies as part of your M&A strategy. To be IPO-eligible you will need all of this along with a trail of revenue and profit performance, and the potential for a post-IPO market capitalization level of at least $200 million.”

“Reverse Mergers (RM) are another source of capital and liquidity. They are not affected by fluctuating market conditions and in part for this reason they have become an alternative to a conventional IPO or sale of company. RMs have now become quite respectable witness the SEC’s endorsement, and are growing quite rapidly as a result of a lack of the IPO alternative for smaller companies. When consolidated with Private Investment for Public Equity (PIPE) they can provide immediate capital infusion”.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Phoenix Marcom Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bridge4Bio Teams with Instream Partners to Focus on Investment Advice

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Paul Carter - PhoenixMarcom.co.uk 
+1 510-559-8599 press[.]bridge4bio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Phoenix Marcom Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Phoenix Marcom Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)